Syros Pharmaceuticals to Present on its Two Lead Programs, SY -1425 and SY -1365, at 21st Congress of the European Hematology Association
SM Investments 1Q Net Profit PHP7.0 Billion, Up 3.6% From Year Ago
SM Prime 1Q Recurring Net Profit Up 12% to PHP5.8 Billion
Its slower cash burn is encouraging, but we remain concerned about end-market demand.
IRA experts weigh in on a tricky situation a client has with the IRS.